Neonatal Screening
8
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
Bilistick Point-of-care System 2.0 Bilirubin Validation
Neonatal Screening of Severe Combined Immunodeficiencies
The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research
Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking
Parent Education and Choice About Newborn Screening and Bloodspot Retention
Amino Acid and Acylcarnitine Profiles in Premature Neonates